• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长效呋塞米与速尿型阿米洛利联合应用:人体药代动力学与药效学研究

Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects.

作者信息

Flouvat B, Roux A, Leneveu A, Prinseau J, Alexandre J A

机构信息

Laboratoire de toxicologie et de pharmacocinétique, Hôpital Ambroise-Paré, Boulogne-Billancourt, France.

出版信息

Fundam Clin Pharmacol. 1991;5(8):741-52. doi: 10.1111/j.1472-8206.1991.tb00762.x.

DOI:10.1111/j.1472-8206.1991.tb00762.x
PMID:1783363
Abstract

The pharmacokinetics and pharmacodynamics of the combination of amiloride (2 x 2.5 mg) and long-acting furosemide (2 x 10 mg) were compared with amiloride (5 mg) and furosemide (20 mg) in 12 healthy male volunteers aged 26.2 +/- 1.6 years and weighing 68.8 +/- 6.2 kg, after random order administration. Furosemide and amiloride plasma or urine concentrations were determined by HPLC with fluorimetric detection. The rate of absorption (tmax = 3 h) and the bioavailability of the two diuretics were not significantly modified by their combination. Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h. The urinary elimination of furosemide was significantly higher in the 2-4 h interval in the combination treatment, accompanying its delayed maximum effect of diuresis. A synergistic effect was observed after the combination administration of the two diuretics; between the 2nd and the 8th hour, the sodium elimination was significantly increased (P less than 0.01) and the potassium excretion was significantly decreased (P = 0.05). After a single dose, no modification of plasma or erythrocyte magnesium levels was observed. This study shows that the combination of the two drugs entails a synergy of their activities which does not involve pharmacokinetic changes.

摘要

在12名年龄为26.2±1.6岁、体重为68.8±6.2 kg的健康男性志愿者中,按照随机顺序给药,比较了阿米洛利(2×2.5 mg)与长效呋塞米(2×10 mg)联合用药与阿米洛利(5 mg)和呋塞米(20 mg)单独用药的药代动力学和药效学。采用高效液相色谱荧光检测法测定呋塞米和阿米洛利的血浆或尿液浓度。两种利尿剂联合使用后,其吸收速率(达峰时间=3小时)和生物利用度未发生显著改变。联合治疗后呋塞米的血浆半衰期为2.77±1.04小时,单独使用时为2.76±0.98小时;阿米洛利的血浆半衰期分别为15.7±4.6小时和14.6±3.7小时。联合治疗时,呋塞米在2-4小时期间的尿排泄量显著更高,同时其利尿最大效应延迟出现。两种利尿剂联合给药后观察到协同效应;在第2至第8小时之间,钠排泄显著增加(P<0.01),钾排泄显著减少(P=0.05)。单次给药后,未观察到血浆或红细胞镁水平的改变。本研究表明,两种药物联合使用可产生协同作用,且不涉及药代动力学变化。

相似文献

1
Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects.长效呋塞米与速尿型阿米洛利联合应用:人体药代动力学与药效学研究
Fundam Clin Pharmacol. 1991;5(8):741-52. doi: 10.1111/j.1472-8206.1991.tb00762.x.
2
[Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].[健康受试者中呋塞米与呋塞米-阿米洛利的药代动力学及对电解质尿分泌影响的比较研究]
Therapie. 1991 Nov-Dec;46(6):475-9.
3
Determination and pharmacokinetics of a furosemide-amiloride drug combination.
J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):383-91. doi: 10.1016/s0378-4347(97)00055-8.
4
Relationship of urinary kallikrein excretion to urinary potassium excretion during furosemide administration with and without amiloride.在使用和不使用氨氯吡咪的情况下给予速尿期间尿激肽释放酶排泄与尿钾排泄的关系。
Arch Int Physiol Biochim. 1987 Mar;95(1):13-8. doi: 10.3109/13813458709075020.
5
Effects of single doses of a 20 mg frusemide/2.5 mg amiloride combination, 20 mg frusemide and placebo on plasma and urine electrolytes in healthy men.单剂量20毫克速尿/2.5毫克阿米洛利组合、20毫克速尿和安慰剂对健康男性血浆及尿液电解质的影响。
J Int Med Res. 1990;18 Suppl 2:3B-9B.
6
Effects of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of furosemide in rats.
J Clin Pharm Ther. 1995 Feb;20(1):13-21. doi: 10.1111/j.1365-2710.1995.tb00620.x.
7
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.托拉塞米和呋塞米在充血性心力衰竭患者中的生物利用度、药代动力学及药效学
Clin Pharmacol Ther. 1995 Jun;57(6):601-9. doi: 10.1016/0009-9236(95)90222-8.
8
Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.托拉塞米与呋塞米在健康志愿者体内的药代动力学和药效学比较。
Arzneimittelforschung. 1988 Jan;38(1A):160-3.
9
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.托拉塞米和呋塞米在利尿剂抵抗性腹水患者中的药代动力学和药效学
J Hepatol. 1996 Oct;25(4):481-90. doi: 10.1016/s0168-8278(96)80207-8.
10
Urinary electrolyte excretion after frusemide, amiloride and a combination of these drugs: an open, crossover study.速尿、氨苯蝶啶及二者联合用药后的尿电解质排泄:一项开放性交叉研究。
Curr Med Res Opin. 1984;9(2):124-31. doi: 10.1185/03007998409109570.